Last 12 months
Inside the activity.
0 purchase rows · 54 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 3 |
| Dec 2025 | 0 | 10 |
| Jan 2026 | 0 | 3 |
| Feb 2026 | 0 | 3 |
| Mar 2026 | 0 | 4 |
| Apr 2026 | 0 | 5 |
| May 2026 | 0 | 12 |
| Jun 2026 | 0 | 2 |
| Jul 2026 | 0 | 4 |
| Aug 2026 | 0 | 6 |
| Sep 2026 | 0 | 1 |
| Oct 2026 | 0 | 1 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 12, 2026 Filed May 12, 2026 20:55 UTC |
Zovighian Bernard JDirector · CEO
|
GiftCommon Stock | 26,640 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-26-005172 · doc4.xml · nonDerivative · entry 4 Zovighian Bernard J · CIK 0001665141 · Director · CEO 10b5-1 filing: Plan reported Ownership: Indirect · By Trust Disclosed balance after: 48,390.5511 Read SEC document |
| May 12, 2026 Filed May 12, 2026 20:55 UTC |
Zovighian Bernard JDirector · CEO
|
GiftCommon Stock | 26,640 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-26-005172 · doc4.xml · nonDerivative · entry 3 Zovighian Bernard J · CIK 0001665141 · Director · CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 99,164.6499 Read SEC document |
| May 11, 2026 Filed May 12, 2026 01:59 UTC |
Ullem Scott B.CVP, Chief Financial Officer
|
Exercise / conversionPerformance Rights · Derivative | 19,830 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-26-005133 · doc4.xml · derivative · entry 4 Ullem Scott B. · CIK 0001446989 · CVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 19,830 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On May 11, 2023, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 6, 2026, the Compensation and Governance Committee of the Board of Directors determined that 167.70% of the target number of shares would vest as of May 11, 2026, and the actual number of shares vested are reflected on this Form 4. F2 · derivative.expiration_date: These Performance Rights expire on May 10, 2030. Read SEC document |
| May 11, 2026 Filed May 12, 2026 01:59 UTC |
Ullem Scott B.CVP, Chief Financial Officer
|
Tax withholdingCommon Stock | 11,004 | $79.96 | $879,879.84 |
DisclosureSEC source: 0001225208-26-005133 · doc4.xml · nonDerivative · entry 2 Ullem Scott B. · CIK 0001446989 · CVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,740 Read SEC document |
| May 11, 2026 Filed May 12, 2026 01:59 UTC |
Ullem Scott B.CVP, Chief Financial Officer
|
Exercise / conversionCommon Stock | 19,830 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-26-005133 · doc4.xml · nonDerivative · entry 1 Ullem Scott B. · CIK 0001446989 · CVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 57,744 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: On May 11, 2023, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 6, 2026, the Compensation and Governance Committee of the Board of Directors determined that 167.70% of the target number of shares would vest as of May 11, 2026, and the actual number of shares vested are reflected on this Form 4. F1 · price: On May 11, 2023, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 6, 2026, the Compensation and Governance Committee of the Board of Directors determined that 167.70% of the target number of shares would vest as of May 11, 2026, and the actual number of shares vested are reflected on this Form 4. Read SEC document |
| May 11, 2026 Filed May 12, 2026 01:33 UTC |
Markowitz WayneCVP, JAPAC
|
SaleCommon Stock | 593 | $79.73 | $47,279.89 |
DisclosureSEC source: 0001225208-26-005132 · doc4.xml · nonDerivative · entry 4 Markowitz Wayne · CIK 0001991414 · CVP, JAPAC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,679.8708 Read SEC document |
| May 11, 2026 Filed May 12, 2026 01:32 UTC |
Zovighian Bernard JDirector · CEO
|
GiftCommon Stock | 5,489 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-26-005131 · doc4.xml · nonDerivative · entry 7 Zovighian Bernard J · CIK 0001665141 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Indirect · By Trust Disclosed balance after: 21,750.5511 Read SEC document |
| May 11, 2026 Filed May 12, 2026 01:32 UTC |
Zovighian Bernard JDirector · CEO
|
GiftCommon Stock | 5,489 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-26-005131 · doc4.xml · nonDerivative · entry 5 Zovighian Bernard J · CIK 0001665141 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 104,795.6499 Read SEC document |
| May 11, 2026 Filed May 12, 2026 01:32 UTC |
Lippis Daniel J.CVP, TAVR
|
Tax withholdingCommon Stock | 362 | $79.96 | $28,945.52 |
DisclosureSEC source: 0001225208-26-005130 · doc4.xml · nonDerivative · entry 1 Lippis Daniel J. · CIK 0002004380 · CVP, TAVR 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,410.9103 Read SEC document |
| May 11, 2026 Filed May 12, 2026 20:55 UTC |
Zovighian Bernard JDirector · CEO
|
Exercise / conversionPerformance Rights · Derivative | 47,207 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-26-005172 · doc4.xml · derivative · entry 8 Zovighian Bernard J · CIK 0001665141 · Director · CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 47,207 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On May 11, 2023, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 6, 2026, the Compensation and Governance Committee of the Board of Directors determined that 167.70% of the target number of shares would vest as of May 11, 2026, and the actual number of shares vested are reflected on this Form 4. F5 · derivative.expiration_date: These Performance Rights expire on May 10, 2030. Read SEC document |
| May 11, 2026 Filed May 12, 2026 20:55 UTC |
Zovighian Bernard JDirector · CEO
|
Tax withholdingCommon Stock | 26,198 | $79.96 | $2,094,792.08 |
DisclosureSEC source: 0001225208-26-005172 · doc4.xml · nonDerivative · entry 2 Zovighian Bernard J · CIK 0001665141 · Director · CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 125,804.6499 Read SEC document |
| May 11, 2026 Filed May 12, 2026 20:55 UTC |
Zovighian Bernard JDirector · CEO
|
Exercise / conversionCommon Stock | 47,207 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-26-005172 · doc4.xml · nonDerivative · entry 1 Zovighian Bernard J · CIK 0001665141 · Director · CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 157,491.6499 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: On May 11, 2023, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 6, 2026, the Compensation and Governance Committee of the Board of Directors determined that 167.70% of the target number of shares would vest as of May 11, 2026, and the actual number of shares vested are reflected on this Form 4. F1 · price: On May 11, 2023, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 6, 2026, the Compensation and Governance Committee of the Board of Directors determined that 167.70% of the target number of shares would vest as of May 11, 2026, and the actual number of shares vested are reflected on this Form 4. Read SEC document |
| May 11, 2026 Filed May 12, 2026 20:52 UTC |
BOBO DONALD E JRCVP,Strategy/Corp Development
|
Exercise / conversionPerformance Rights · Derivative | 13,457 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-26-005171 · doc4.xml · derivative · entry 5 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 13,457 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On May 11, 2023, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 6, 2026, the Compensation and Governance Committee of the Board of Directors determined that 167.70% of the target number of shares would vest as of May 11, 2026, and the actual number of shares vested are reflected on this Form 4. F2 · derivative.expiration_date: These Performance Rights expire on May 10, 2030. Read SEC document |
| May 11, 2026 Filed May 12, 2026 20:52 UTC |
BOBO DONALD E JRCVP,Strategy/Corp Development
|
Tax withholdingCommon Stock | 7,469 | $79.96 | $597,221.24 |
DisclosureSEC source: 0001225208-26-005171 · doc4.xml · nonDerivative · entry 2 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,766.2532 Read SEC document |
| May 11, 2026 Filed May 12, 2026 20:52 UTC |
BOBO DONALD E JRCVP,Strategy/Corp Development
|
Exercise / conversionCommon Stock | 13,457 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-26-005171 · doc4.xml · nonDerivative · entry 1 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,235.2532 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: On May 11, 2023, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 6, 2026, the Compensation and Governance Committee of the Board of Directors determined that 167.70% of the target number of shares would vest as of May 11, 2026, and the actual number of shares vested are reflected on this Form 4. F1 · price: On May 11, 2023, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 6, 2026, the Compensation and Governance Committee of the Board of Directors determined that 167.70% of the target number of shares would vest as of May 11, 2026, and the actual number of shares vested are reflected on this Form 4. Read SEC document |
| May 11, 2026 Filed May 12, 2026 20:50 UTC |
Chopra DaveenCVP, TMTT & Surgical
|
Exercise / conversionPerformance Rights · Derivative | 13,583 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-26-005170 · doc4.xml · derivative · entry 3 Chopra Daveen · CIK 0001740963 · CVP, TMTT & Surgical 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 13,583 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On May 11, 2023, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 6, 2026, the Compensation and Governance Committee of the Board of Directors determined that 167.70% of the target number of shares would vest as of May 11, 2026, and the actual number of shares vested are reflected on this Form 4. F2 · derivative.expiration_date: These Performance Rights expire on May 10, 2030. Read SEC document |
| May 11, 2026 Filed May 12, 2026 20:50 UTC |
Chopra DaveenCVP, TMTT & Surgical
|
Tax withholdingCommon Stock | 7,538 | $79.96 | $602,738.48 |
DisclosureSEC source: 0001225208-26-005170 · doc4.xml · nonDerivative · entry 2 Chopra Daveen · CIK 0001740963 · CVP, TMTT & Surgical 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,824 Read SEC document |
| May 11, 2026 Filed May 12, 2026 20:50 UTC |
Chopra DaveenCVP, TMTT & Surgical
|
Exercise / conversionCommon Stock | 13,583 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-26-005170 · doc4.xml · nonDerivative · entry 1 Chopra Daveen · CIK 0001740963 · CVP, TMTT & Surgical 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 53,362 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: On May 11, 2023, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 6, 2026, the Compensation and Governance Committee of the Board of Directors determined that 167.70% of the target number of shares would vest as of May 11, 2026, and the actual number of shares vested are reflected on this Form 4. F1 · price: On May 11, 2023, the Reporting Person was granted a target number of shares covered by restricted stock units with performance-based vesting requirements over a three-year performance period. On May 6, 2026, the Compensation and Governance Committee of the Board of Directors determined that 167.70% of the target number of shares would vest as of May 11, 2026, and the actual number of shares vested are reflected on this Form 4. Read SEC document |
| May 08, 2026 Filed May 9, 2026 01:18 UTC |
VALERIANI NICHOLAS JDirector
|
GrantCommon Stock | 5,127 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-26-005055 · doc4.xml · nonDerivative · entry 1 VALERIANI NICHOLAS J · CIK 0001263149 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 84,423 F1 · shares: These restricted stock units were granted on May 8, 2026 under the Edwards Lifesciences Corporation 2020 Nonemployee Directors Stock Incentive Program. They are scheduled to become 100% vested after the earlier of one year from the grant date or the Issuer's next annual meeting of stockholders. Read SEC document |
| May 08, 2026 Filed May 9, 2026 01:18 UTC |
Sequeira RamonaDirector
|
GrantCommon Stock | 3,251 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-26-005054 · doc4.xml · nonDerivative · entry 1 Sequeira Ramona · CIK 0001811081 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,779 F1 · shares: These restricted stock units were granted on May 8, 2026 under the Edwards Lifesciences Corporation 2020 Nonemployee Directors Stock Incentive Program. They are scheduled to become 100% vested after the earlier of one year from the grant date or the Issuer's next annual meeting of stockholders. Read SEC document |
| May 08, 2026 Filed May 9, 2026 01:18 UTC |
LORANGER STEVEN RDirector
|
GrantCommon Stock | 1,064 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-26-005053 · doc4.xml · nonDerivative · entry 2 LORANGER STEVEN R · CIK 0001226924 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,997 F2 · shares: This restricted stock award was granted on May 8, 2026 under the Edwards Lifesciences Corporation 2020 Nonemployee Directors Stock Incentive Program and is scheduled to become 100% vested after the earlier of one year from the grant date or the Issuer's next annual meeting of stockholders. Read SEC document |
| May 08, 2026 Filed May 9, 2026 01:18 UTC |
LORANGER STEVEN RDirector
|
GrantCommon Stock | 3,251 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-26-005053 · doc4.xml · nonDerivative · entry 1 LORANGER STEVEN R · CIK 0001226924 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,933 F1 · shares: These restricted stock units were granted on May 8, 2026 under the Edwards Lifesciences Corporation 2020 Nonemployee Directors Stock Incentive Program. They are scheduled to become 100% vested after the earlier of one year from the grant date or the Issuer's next annual meeting of stockholders. Read SEC document |
| May 08, 2026 Filed May 9, 2026 01:17 UTC |
LAVIOLETTE PAUL ADirector
|
GrantCommon Stock | 3,251 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-26-005052 · doc4.xml · nonDerivative · entry 1 LAVIOLETTE PAUL A · CIK 0001191249 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,552 F1 · shares: These restricted stock units were granted on May 8, 2026 under the Edwards Lifesciences Corporation 2020 Nonemployee Directors Stock Incentive Program. They are scheduled to become 100% vested after the earlier of one year from the grant date or the Issuer's next annual meeting of stockholders. Read SEC document |
| May 08, 2026 Filed May 9, 2026 01:17 UTC |
STONE HEISZ LESLIEDirector
|
GrantCommon Stock | 3,251 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-26-005051 · doc4.xml · nonDerivative · entry 1 STONE HEISZ LESLIE · CIK 0001235408 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,199 F1 · shares: These restricted stock units were granted on May 8, 2026 under the Edwards Lifesciences Corporation 2020 Nonemployee Directors Stock Incentive Program. They are scheduled to become 100% vested after the earlier of one year from the grant date or the Issuer's next annual meeting of stockholders. Read SEC document |
| May 08, 2026 Filed May 9, 2026 01:17 UTC |
GALLAHUE KIERANDirector
|
GrantCommon Stock | 1,064 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-26-005050 · doc4.xml · nonDerivative · entry 2 GALLAHUE KIERAN · CIK 0001308428 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,315 F2 · shares: This restricted stock award was granted on May 8, 2026 under the Edwards Lifesciences Corporation 2020 Nonemployee Directors Stock Incentive Program and is scheduled to become 100% vested after the earlier of one year from the grant date or the Issuer's next annual meeting of stockholders. Read SEC document |
| May 08, 2026 Filed May 9, 2026 01:17 UTC |
GALLAHUE KIERANDirector
|
GrantCommon Stock | 3,251 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-26-005050 · doc4.xml · nonDerivative · entry 1 GALLAHUE KIERAN · CIK 0001308428 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,251 F1 · shares: These restricted stock units were granted on May 8, 2026 under the Edwards Lifesciences Corporation 2020 Nonemployee Directors Stock Incentive Program. They are scheduled to become 100% vested after the earlier of one year from the grant date or the Issuer's next annual meeting of stockholders. Read SEC document |
| May 08, 2026 Filed May 9, 2026 01:17 UTC |
Feinberg David TDirector
|
GrantCommon Stock | 3,251 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-26-005049 · doc4.xml · nonDerivative · entry 1 Feinberg David T · CIK 0001486426 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,087 F1 · shares: These restricted stock units were granted on May 8, 2026 under the Edwards Lifesciences Corporation 2020 Nonemployee Directors Stock Incentive Program. They are scheduled to become 100% vested after the earlier of one year from the grant date or the Issuer's next annual meeting of stockholders. Read SEC document |
| May 08, 2026 Filed May 9, 2026 01:17 UTC |
BOBO DONALD E JRCVP,Strategy/Corp Development
|
Tax withholdingCommon Stock | 1,038 | $82.76 | $85,904.88 |
DisclosureSEC source: 0001225208-26-005048 · doc4.xml · nonDerivative · entry 3 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,778.2532 Read SEC document |
| May 08, 2026 Filed May 9, 2026 01:16 UTC |
Ullem Scott B.CVP, Chief Financial Officer
|
Tax withholdingCommon Stock | 1,661 | $82.76 | $137,464.36 |
DisclosureSEC source: 0001225208-26-005047 · doc4.xml · nonDerivative · entry 2 Ullem Scott B. · CIK 0001446989 · CVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,914 Read SEC document |
| May 08, 2026 Filed May 9, 2026 01:16 UTC |
Davis Leslie C.Director
|
GrantCommon Stock | 3,251 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-26-005046 · doc4.xml · nonDerivative · entry 1 Davis Leslie C. · CIK 0002021765 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,834 F1 · shares: These restricted stock units were granted on May 8, 2026 under the Edwards Lifesciences Corporation 2020 Nonemployee Directors Stock Incentive Program. They are scheduled to become 100% vested after the earlier of one year from the grant date or the Issuer's next annual meeting of stockholders. Read SEC document |
| May 08, 2026 Filed May 9, 2026 01:16 UTC |
Lippis Daniel J.CVP, TAVR
|
Tax withholdingCommon Stock | 450 | $82.76 | $37,242.00 |
DisclosureSEC source: 0001225208-26-005045 · doc4.xml · nonDerivative · entry 3 Lippis Daniel J. · CIK 0002004380 · CVP, TAVR 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,772.9103 Read SEC document |
| May 08, 2026 Filed May 9, 2026 01:16 UTC |
Dahl Andrew M.SVP, Corporate Controller
|
Tax withholdingCommon Stock | 289 | $82.76 | $23,917.64 |
DisclosureSEC source: 0001225208-26-005044 · doc4.xml · nonDerivative · entry 3 Dahl Andrew M. · CIK 0002022347 · SVP, Corporate Controller 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,901.6214 Read SEC document |
| May 08, 2026 Filed May 9, 2026 01:16 UTC |
Chopra DaveenCVP, TMTT & Surgical
|
Tax withholdingCommon Stock | 1,141 | $82.76 | $94,429.16 |
DisclosureSEC source: 0001225208-26-005043 · doc4.xml · nonDerivative · entry 3 Chopra Daveen · CIK 0001740963 · CVP, TMTT & Surgical 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,779 Read SEC document |
| May 08, 2026 Filed May 9, 2026 01:15 UTC |
Bruls AnnetteCVP, EMEACLA
|
Tax withholdingCommon Stock | 84 | $82.76 | $6,951.84 |
DisclosureSEC source: 0001225208-26-005042 · doc4.xml · nonDerivative · entry 2 Bruls Annette · CIK 0002032351 · CVP, EMEACLA 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,737 Read SEC document |
| May 08, 2026 Filed May 12, 2026 01:33 UTC |
Markowitz WayneCVP, JAPAC
|
Tax withholdingCommon Stock | 226 | $82.76 | $18,703.76 |
DisclosureSEC source: 0001225208-26-005132 · doc4.xml · nonDerivative · entry 3 Markowitz Wayne · CIK 0001991414 · CVP, JAPAC 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,272.8708 Read SEC document |
| May 08, 2026 Filed May 12, 2026 01:32 UTC |
Zovighian Bernard JDirector · CEO
|
GiftCommon Stock | 4,222 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-26-005131 · doc4.xml · nonDerivative · entry 6 Zovighian Bernard J · CIK 0001665141 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Indirect · By Trust Disclosed balance after: 16,261.5511 Read SEC document |
| May 08, 2026 Filed May 12, 2026 01:32 UTC |
Zovighian Bernard JDirector · CEO
|
Tax withholdingCommon Stock | 5,398 | $82.76 | $446,738.48 |
DisclosureSEC source: 0001225208-26-005131 · doc4.xml · nonDerivative · entry 4 Zovighian Bernard J · CIK 0001665141 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 110,284.6499 Read SEC document |
| May 08, 2026 Filed May 12, 2026 01:32 UTC |
Zovighian Bernard JDirector · CEO
|
GiftCommon Stock | 4,222 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-26-005131 · doc4.xml · nonDerivative · entry 3 Zovighian Bernard J · CIK 0001665141 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 115,682.6499 Read SEC document |
| May 07, 2026 Filed May 9, 2026 01:17 UTC |
BOBO DONALD E JRCVP,Strategy/Corp Development
|
GrantPerformance Rights · Derivative | 7,850 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-26-005048 · doc4.xml · derivative · entry 7 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,850 Underlying: Common Stock · 7,850 shares Expires not disclosed F3 · derivative.exercise_price: Reflects the target number of shares (the Target Award) covered by restricted stock units granted on May 7, 2026 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to vest on May 7, 2029. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 200% of the Target Awards. F3 · derivative.expiration_date: Reflects the target number of shares (the Target Award) covered by restricted stock units granted on May 7, 2026 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to vest on May 7, 2029. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 200% of the Target Awards. Read SEC document |
| May 07, 2026 Filed May 9, 2026 01:17 UTC |
BOBO DONALD E JRCVP,Strategy/Corp Development
|
GrantEmployee Stock Option (Right to Acquire) · Derivative | 44,000 | $0.00 Strike: $82.76 | $0.00 |
DisclosureSEC source: 0001225208-26-005048 · doc4.xml · derivative · entry 6 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,000 Underlying: Common Stock · 44,000 shares Expires 2033-05-06 F2 · derivative.exercise_date: These options were granted on May 7, 2026 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one month after the grant date in 36 approximately equal monthly installments. Read SEC document |
| May 07, 2026 Filed May 9, 2026 01:17 UTC |
BOBO DONALD E JRCVP,Strategy/Corp Development
|
Tax withholdingCommon Stock | 831 | $83.20 | $69,139.20 |
DisclosureSEC source: 0001225208-26-005048 · doc4.xml · nonDerivative · entry 2 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,816.2532 Read SEC document |
| May 07, 2026 Filed May 9, 2026 01:17 UTC |
BOBO DONALD E JRCVP,Strategy/Corp Development
|
GrantCommon Stock | 7,850 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-26-005048 · doc4.xml · nonDerivative · entry 1 BOBO DONALD E JR · CIK 0001196661 · CVP,Strategy/Corp Development 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,647.2532 F1 · shares: These restricted stock units were granted on May 7, 2026 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments. Read SEC document |
| May 07, 2026 Filed May 9, 2026 01:16 UTC |
Ullem Scott B.CVP, Chief Financial Officer
|
Tax withholdingCommon Stock | 1,373 | $83.20 | $114,233.60 |
DisclosureSEC source: 0001225208-26-005047 · doc4.xml · nonDerivative · entry 1 Ullem Scott B. · CIK 0001446989 · CVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,575 Read SEC document |
| May 07, 2026 Filed May 9, 2026 01:16 UTC |
Lippis Daniel J.CVP, TAVR
|
GrantPerformance Rights · Derivative | 7,850 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-26-005045 · doc4.xml · derivative · entry 5 Lippis Daniel J. · CIK 0002004380 · CVP, TAVR 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,850 Underlying: Common Stock · 7,850 shares Expires not disclosed F3 · derivative.exercise_price: Reflects the target number of shares (the Target Award) covered by restricted stock units granted on May 7, 2026 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to vest on May 7, 2029. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 200% of the Target Awards. F3 · derivative.expiration_date: Reflects the target number of shares (the Target Award) covered by restricted stock units granted on May 7, 2026 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to vest on May 7, 2029. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 200% of the Target Awards. Read SEC document |
| May 07, 2026 Filed May 9, 2026 01:16 UTC |
Lippis Daniel J.CVP, TAVR
|
GrantEmployee Stock Option (Right to Acquire) · Derivative | 39,900 | $0.00 Strike: $82.76 | $0.00 |
DisclosureSEC source: 0001225208-26-005045 · doc4.xml · derivative · entry 4 Lippis Daniel J. · CIK 0002004380 · CVP, TAVR 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,900 Underlying: Common Stock · 39,900 shares Expires 2033-05-06 F2 · derivative.exercise_date: These options were granted on May 7, 2026 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments. Read SEC document |
| May 07, 2026 Filed May 9, 2026 01:16 UTC |
Lippis Daniel J.CVP, TAVR
|
Tax withholdingCommon Stock | 309 | $83.20 | $25,708.80 |
DisclosureSEC source: 0001225208-26-005045 · doc4.xml · nonDerivative · entry 2 Lippis Daniel J. · CIK 0002004380 · CVP, TAVR 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,222.9103 Read SEC document |
| May 07, 2026 Filed May 9, 2026 01:16 UTC |
Lippis Daniel J.CVP, TAVR
|
GrantCommon Stock | 7,850 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-26-005045 · doc4.xml · nonDerivative · entry 1 Lippis Daniel J. · CIK 0002004380 · CVP, TAVR 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,531.9103 F1 · shares: These restricted stock units were granted on May 7, 2026 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments. Read SEC document |
| May 07, 2026 Filed May 9, 2026 01:16 UTC |
Dahl Andrew M.SVP, Corporate Controller
|
GrantEmployee Stock Option (Right to Acquire) · Derivative | 6,745 | $0.00 Strike: $82.76 | $0.00 |
DisclosureSEC source: 0001225208-26-005044 · doc4.xml · derivative · entry 4 Dahl Andrew M. · CIK 0002022347 · SVP, Corporate Controller 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,745 Underlying: Common Stock · 6,745 shares Expires 2033-05-06 F2 · derivative.exercise_date: These options were granted on May 7, 2026 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments. Read SEC document |
| May 07, 2026 Filed May 9, 2026 01:16 UTC |
Dahl Andrew M.SVP, Corporate Controller
|
GrantCommon Stock | 3,020 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-26-005044 · doc4.xml · nonDerivative · entry 2 Dahl Andrew M. · CIK 0002022347 · SVP, Corporate Controller 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,190.6214 F1 · shares: These restricted stock units were granted on May 7, 2026 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments. Read SEC document |
| May 07, 2026 Filed May 9, 2026 01:16 UTC |
Dahl Andrew M.SVP, Corporate Controller
|
GrantCommon Stock | 3,985 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-26-005044 · doc4.xml · nonDerivative · entry 1 Dahl Andrew M. · CIK 0002022347 · SVP, Corporate Controller 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,170.6214 F1 · shares: These restricted stock units were granted on May 7, 2026 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.